Table 1.
Evaluation of the markers using the discovery set with 12 non-lepidic AD and three PDSCC patients
| AD markers | (Marker status) | (+) | (−) | Sensitivity | Specificity | PPV | NPV | Accuracy | ||
| (subtype) | AD | SCC | AD | SCC | (95 % CI†) | (95 % CI) | (95 % CI) | (95 % CI) | (95 % CI) | |
| ST6GALNAC1* | 8 | 0 | 4 | 3 | 0.667 (0.349–0.901) | 1.000 (0.292–1.000) | 1.000 (0.631–1.000) | 0.429 (0.099–0.816) | 0.733 (0.099–0.816) | |
| TTF-1 | 5 | 0 | 7 | 3 | 0.417 (0.152–0.723) | 1.000 (0.292–1.000) | 1.000 (0.478–1.000) | 0.300 (0.067–0.652) | 0.533 (0.266–0.787) | |
| napsin A | 2 | 0 | 10 | 3 | 0.167 (0.021–0.484) | 1.000 (0.292–1.000) | 1.000 (0.158–1.000) | 0.231 (0.050–0.538) | 0.333 (0.118–0.616) | |
| SCC markers | (Marker status) | (+) | (−) | Sensitivity | Specificity | PPV | NPV | Accuracy | ||
| (subtype) | SCC | AD | SCC | AD | (95 % CI) | (95 % CI) | (95 % CI) | (95 % CI) | (95 % CI) | |
| SPATS2* | 2 | 0 | 1 | 12 | 0.667 (0.094–0.992) | 1.000 (0.735–1.000) | 1.000 (0.158–1.000) | 0.923 (0.640–0.998) | 0.933 (0.681–0.998) | |
| CK5 | 1 | 0 | 2 | 12 | 0.333 (0.008–0.906) | 1.000 (0.735–1.000) | 1.000 (0.025–1.000) | 0.857 (0.572–0.982) | 0.867 (0.595–0.983) | |
| DSG3 | 0 | 0 | 3 | 12 | 0.000 (0.000–0.708) |
1.000 (0.735–1.000) |
N.A. | 0.800 (0.519–0.957) | 0.800 (0.519–0.957) | |
| p40 | 1 | 0 | 2 | 12 | 0.333 (0.008–0.906) |
1.000 (0.735–1.000) |
1.000 (0.025–1.000) |
0.857 (0.572–0.982) |
0.867 (0.595–0.983) | |
| CK6 | 0 | 0 | 3 | 12 | 0.000 (0.000–0.708) | 1.000 (0.735–1.000) | N.A. | 0.800 (0.519–0.957) | 0.800 (0.519–0.957) | |
PPV Positive predictive value, NPV Negative predictive value, 95 % CI 95 % confidence interval, N.A Not available
†:95 % CIs of sensitivity, specificity, PPV, NPV and accuracy were estimated by the Clopper-Pearson method
* Novel biomarkers identified in the present study